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A simple method has been developed and validated for quantitative determination of
lumefantrine in antimalarial finished pharmaceutical products using gas chromatography
coupled to flame ionization detector. Lumefantrine was silylated with N,Oebis(trimethyl-
silyl)trifluoro-acetamide at 70C for 30 minutes, and chromatographic separation was
conducted on a fused silica capillary (HP-5, 30 m length  0.32 mm i.d., 0.25 mm film
thickness) column. Evaluation of the method within analytical quality-by-design princi-
ples, including a central composite face-centered design for the sample derivatization
process and PlacketteBurman robustness verification of the chromatographic conditions,
indicated that the method has acceptable specificity toward excipients and degradants,
accuracy [mean recovery ¼ 99.5%, relative standard deviation (RSD) ¼ 1.0%], linearity
(¼0.9986), precision (intraday ¼ 96.1% of the label claim, RSD ¼ 0.9%; interday ¼ 96.3% label
claim, RSD ¼ 0.9%), and high sensitivity with detection limits of 0.01 mg/mL. The developed
method was successfully applied to analyze the lumefantrine content of marketed fixed-
dose combination antimalarial finished pharmaceutical products.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
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There were an estimated 216 million episodes of malaria in
2010, of which approximately 81%, or 174 million cases, were
in the African Region. An estimated 655,000 malaria deaths
were recorded in 2010, of which 91%were in Africa. Moreover,
about 60% of the cases of malaria worldwide and >80% of
malaria deaths occur in Africa, south of the Sahara. Approxi-
mately 86% of malaria deaths globally were of children under
5 years of age; most of these are caused by infection with
Plasmodium falciparum and Plasmodium vivax [1e7].
The World Health Organization has recommended that all
antimalarials should consist of a combination of an artemi-
sinin derivative with a codrug such as lumefantrine, amo-
diaquine, or mefloquine [8]. A combination consisting of b-
artemether and lumefantrine has been proved to be highly
efficacious in children and adults, even against multidrug-
resistant strains of P. falciparum [9]. Therefore, lumefantrine-
containing combinations are incorporated in the World
Health Organization essential drug list for the treatment of
malaria in endemic areas of the tropical climate.
Lumefantrine, also called benflumetol, was first synthe-
sized in the 1970s by the Academy of Military Medical Sci-
ences, Beijing, China, and registered in China for the
treatment of malaria in 1987. It is a racemic aromatic fluorene
derivative, named (Z)-2-(dibutylamino)-1-[2,7-dichloro-9-(4-
chlorobenzylidene)-9H-fluoren-4-yl]ethanol (Fig. 1) [10].
Structurally, physicochemically, and pharmacologically,
lumefantrine belongs to the aryl amino alcohol group of
antimalarial agents [11].
Worldwide malaria control programs are facing one of the
greatest health care challenges due to the increasing problem
of resistance in many parts of the world and the limited
number of antimalarial medicines available. This has led to
increasing difficulties in developing antimalarial treatmentFig. 1 e Chemical structure of lumefantrine and the relatepolicies and providing prompt and effective treatment to all in
need [5]. This increase in resistance can partially be attributed
to substandard antimalarial drugs, resulting in treatment
failure and ultimately increasedmorbidity andmortality [6,7].
Rapid identification of these substandard antimalarial medi-
cines combined with regulatory measures is of paramount
importance to combat this problem [6]. Therefore, appropriate
analytical methods are required to evaluate the quality.
Many methods have already been reported for the deter-
mination of lumefantrine in finished pharmaceutical prod-
ucts (FPPs) [12e14]. High-performance liquid chromatography
(HPLC) methods are also reported for the simultaneous
determination of lumefantrine and b-artemether in
artemisinin-based antimalarial fixed-dose combination (FDC)
products [15,16]. Microemulsion electrokinetic chromatog-
raphy was developed as an alternative method to liquid
chromatography for the determination of lumefantrine [17].
However, at this moment, there is no gas chromatographic
(GC) assay method available, despite GC being a suitable
technique in poor resource economies due to its ease of
operation and maintenance, lower use costs, and high sepa-
ration efficiency [18]. Analysis of poorly soluble and weakly
basic drugs by reverse-phase liquid chromatography remains
a problem [19,20]. Lumefantrine is a nitrogen-containing basic
compound [10], which can form asymmetrical peaks that can
compromise separation and quantitation when analyzed
using reverse-phase HPLC [21]. Moreover, selectivity issues are
prominent in HPLC methods for the simultaneous analysis of
b-artemether and lumefantrine in FPPs as a result of the
presence of multiple related impurities and excipients, espe-
cially in pediatric formulations [16].
This paper reports a GC coupled to flame ionization de-
tector (GC-FID) method for the quantitative determination of
lumefantrine in antimalarial FPPs using silylation with N,O-
bis(trimethyl-silyl)trifluoro-acetamide (BSTFA).d impurities. DB ¼ desbenzyl; DBK ¼ desbenzylketo.
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2.1. Materials and reagents
Lumefantrine active pharmaceutical ingredient (API) and Co-
Artesiane FPP powder for oral suspension were obtained
from Dafra Pharma International (B-2300 Turnhout, Belgium).
The standards of desbenzylketo (DBK) impurity, N-oxide
lumefantrine, and desbenzyl (DB) impurity were prepared in
house at the Laboratory of Drug Quality and Registration
(DruQuaR) of Ghent University, Ghent, Belgium [14]. Coartem
and Artemine samples were collected in Ethiopia. United
States Pharmacopoeia Medicines Compendium (USP-MC)
standard of impurity A was purchased from US Pharmaco-
poeia (Basel, Switzerland). Analytical solutions were prepared
using unstabilized HPLC-grade tetrahydrofuran (THF; Fisher
Scientific, Leicestershire, UK), and derivatization was per-
formed using extra pure BSTFA (Fisher Scientific).
2.2. Gas chromatography
An Agilent 7820 GC system (Agilent Technologies, Waldbronn,
Germany) was used to perform the analysis with a liquid
autosampler. Samples were introduced in a split/splitless in-
jection port, and detectionwas performed bymeans of FID. An
HP-5 (30 m length  0.32 mm i.d., 0.25 mm film thickness)
column (Agilent Technologies) was used for separation. The
output signal was recorded and processed using EZChrom
Elite software (Agilent Technologies, Santa Clara, CA, USA).
The column oven was programmed with an initial column
oven temperature of 80C for 1minute, and increased to 325C
at a rate of 10C/min,holdingat 325C for 9.5minutes. The total
run time was 35 minutes. The injector and detector tempera-
tures were kept at 300C and 340C, respectively. Helium (Air
Products and Chemicals, Allentown, PA, USA) was used as a
carrier gas with a head pressure of 106.7 kPa resulting in an
initial column flow of 3.2 mL/min and an average velocity of
50 cm/s. Helium was also used as a makeup gas for the FID
detector. The makeup gas flow rate was 25 mL/min, while for
hydrogen and air the flow was 30 mL/min and 400 mL/min,
respectively. The split ratio was set at 10:1, and a 4 mm i.d.
deactivated open-glass tube liner, packed with fused silica
wool, was employed. Samples were injected by the in-
strument's autosamplerwith an injection volumeof 1.0 mL, and
THF was used to rinse the syringe between injections.
2.3. Solutions
2.3.1. Preparation of lumefantrine standard solution
Lumefantrine standard solution was prepared at 100 mg/mL
concentration in THF. This standard solution (250.0 mL) was
transferred into a microvial and evaporated to dryness under
nitrogen to obtain the residue, providing the final concentra-
tion of 500 mg/mL after derivatization.
2.3.2. Preparation of lumefantrine test sample solution
Four samples of FDC tablets (Coartem and Artemine) con-
taining 120 mg of lumefantrine per tablet and one sample of
powder for oral suspension (Co-Artesiane) containing 1080mg
of lumefantrine per bottle were analyzed using the developedGC-FID method. For this, a homogeneous FPP powder weight
equivalent to 10.0 mg lumefantrine was accurately weighed
and transferred to a 10.0 mL volumetric flask. THF was added,
shaken for 5 minutes and diluted to volume using the same
solvent. The mixture was centrifuged (3 minutes at 1914 g),
and a test sample solution was prepared at 100 mg/mL con-
centration (10  dilution) in THF. This test sample solution
(250.0 mL) was transferred into a microvial and evaporated to
dryness under nitrogen to obtain the residue, providing the
final concentration of 500 mg/mL after derivatization.
2.3.3. Preparation of lumefantrine impurity solutions
Four different lumefantrine impurity [DB derivative, lume-
fantrine USP-MC related impurity A (alcohol isomer),N-oxide-
lumefantrine, and DBK derivative] solutions were prepared at
1 mg/mL concentration in THF [14]. Each of these lumefan-
trine impurity solutions (25.0 mL) was quantitatively trans-
ferred into amicrovial and evaporated to dryness under liquid
nitrogen to obtain the residue, providing the final concentra-
tion of 500 mg/mL after derivatization.
This solution can also be used as a system suitability so-
lution as part of the control strategy of analytical quality-by-
design approach.
2.4. Derivatization
The BSTFA derivatives of standards and sample solutions
were prepared from the dry residues obtained as described
above by reacting with 50.0 mL BSTFA solution in airtight glass
vials at 70C for 30minutes in an oven. The resulting solutions
were cooled and injected into GC without removing any
excess of the derivatizing agent.
For optimization and robustness evaluation of the sample
derivatization process, a central composite face-centered
design with 11 runs including three center points was used
for evaluating the influence of incubation time (minutes) and
temperature (C). A lumefantrine reference standard solution
at 100% label claim (lc) was prepared and analyzed using the
different experimental composite face-centered conditions
indicated in the supplementary material online. Peak area for
the main lumefantrine peak and the quantitative presence of
other peaks (with a reporting threshold of 0.1% with reference
to the main peak) were evaluated as responses.
2.5. Validation
Validation of the method was performed based on the Inter-
national Conference on Harmonization guideline [22].
2.5.1. Linearity of calibration curve
From a stock solution containing 100 mg/mL lumefantrine in
THF, different aliquots were transferred into a microvial and
evaporatedtodrynessunder liquidnitrogentoobtaintheresidue,
providing the final concentrations of 400 mg/mL, 450 mg/mL, 500
(100% lc), 550 mg/mL, and 600 mg/mL after derivatization. Calibra-
tion curves for concentration versus peak areawere plotted, and
the obtained datawere subjected to linear regression analysis.
2.5.2. Precision
For intraday precision, six sample solutions (n ¼ 6) were
prepared at 500 mg/mL lumefantrine concentration after
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day precision was evaluated in 3 consecutive days (n ¼ 18).
Lumefantrine concentrations were determined and relative
standard deviations (RSDs) calculated.
2.5.3. Accuracy (recovery test)
Accuracy was tested by recovery experiments where lume-
fantrine reference solutions were added to a placebo sample
at three levels: 75%, 100%, and 125% lc. At each level, samples
were prepared in duplicate and recovery percentage was
calculated.
2.5.4. Specificity
Specificity of the method was evaluated by injecting lume-
fantrine reference standard solution and its impurity solu-
tions (DB, USP-MC impurity A, N-oxide-lumefantrine, and
DBK), both separately and mixed.
2.5.5. Limit of detection and limit of quantitation
Standard solutions of lumefantrine were prepared by serial
dilutions, with concentrations ranging from 10 mg/mL to
0.05 mg/mL after derivatization, and injected onto the GC
system. The limit of detection (LoD) was defined as the
concentration for which a signal-to-noise ratio of 3 was
obtained, and the limit of quantitation (LoQ) was considered
to be the concentration at which the signal-to-noise ratio
was 10.
2.5.6. Robustness
For robustness evaluation, a PlacketteBurman (fractional
factorial) experimental design consisting of 11 runs, including
three center points, was used to investigate four factors:
injector temperature (C), final column temperature (C),
temperature gradient (C/min), and pressure (kPa) (Modde
version 8; Umetrics Inc., San Jose, CA, USA). Two test solutions
[lumefantrine reference standard solution at 100% lc and a
solution containing a mixture of lumefantrine (at 100% lc) and
its related impurities (at 1% lc each)] were prepared and
analyzed using different experimental conditions by varying
the different analytical parameters: injection temperature
(290C, 300C, and 310C), final column temperature (320C,
325C, and 330C), temperature gradient (8C/min, 10C/min,
and 12C/min), and pressure (102 kPa, 107 kPa, and 112 kPa).
Chromatographic resolution (between lumefantrine peak and
two related impurities, N-oxide lumefantrine and USP-MC
impurity A) (Rs), retention time (RT), peak asymmetry (As),
peak area of lumefantrine, and LoD for the two lumefantrine
impurities (N-oxide lumefantrine and USP-MC impurity A)
were evaluated under each condition.Table 1 e RT and RRF for lumefantrine and its related impuriti
Compound DB DBK N-oxide lumef
RT (min) 20.14 20.54 23.78
RRF 0.97 0.56 0.57
DB ¼ desbenzyl; DBK ¼ desbenzylketo; GC-FID ¼ gas chromatography c
RT ¼ retention time.3. Results and discussion
3.1. Method of development
The analytical target profile was to develop a stability-
indicating quantitative assay for lumefantrine in FPPs that
can be used in poor resource economies. The GC-FID meth-
odology is thus an appropriate technique. The quality target
method profile includes that the method should be Interna-
tional Conference on Harmonization validatable within a
goodmanufacturing practices (GMP) environment of a Quality
Control laboratory, including compliance with general phar-
macopeial chromatographic requirements such as minimal
resolution and maximal asymmetry.
As lumefantrine has relatively high melting (128e132C)
and boiling (642.5C) points at 760 mmHg [23,24], and a free
alcohol functional group in its structure (Fig. 1) that affects the
inherent volatility of the compound [25], direct GC analysis
without derivatization was unsuccessful. Using silylation re-
actions [26,27], the nonvolatile and unstable (degrading at
200e300C) lumefantrine molecule could, however, be suc-
cessfully analyzed with GC. The widely available BSTFA was
used as a derivatization reagent in our GC-FID method.
To develop the stability-indicating GC-FID assay for lume-
fantrine, different chromatographic factors were initially
evaluated using a one-factor-at-a-time approach. These fac-
tors include injection port (temperatures ranging from 150C
to 400C were tested) and oven program. In the final method,
lumefantrine eluted at an RT of 26.0 minutes. RT and relative
response factor, defined as the ratio of the response of the
impurity and the API under identical chromatographic con-
ditions [28], values for lumefantrine and its related impurities
are presented in Table 1. All the lumefantrine-related impu-
rities (DB, USP-MC impurity A, N-oxide-lumefantrine, and
DBK) were eluting at different RTs without any interference
with the lumefantrine main peak. The run time of analysis
was 35 minutes. Moreover, relative response factor values
were established to control lumefantrine-related impurities in
the absence of reference impurity standards (due to high cost
and stability of the standards, and difficulty in the isolation of
these standards for usage). A typical chromatogram obtained
for a mixture of lumefantrine API and its related impurities is
presented in Fig. 2.
3.2. Validation
3.2.1. Linearity
A linear correlationwas found between the peak areas and the
concentrations of lumefantrine, in the assayed rangees using GC-FID analytics.
antrine Lumefantrine USP-MC impurity A
26.04 26.25
1.00 0.76
oupled to flame ionization detector; RRF ¼ relative response factor;
Fig. 2 e GC-FID chromatogram of BSTFA-derivatizedmixture of lumefantrine API (RT 26.0minutes) and its related impurities
solution: DB (20.1minutes), DBK (20.5minutes),N-oxide lumefantrine (three peaks at RT 23.8minutes, 25.8minutes, and 26.4
minutes), and USP-MC impurity A (26.3 minutes). BSTFA¼ N,O-bis(trimethyl-silyl)trifluoro-acetamide; DB ¼ desbenzyl;
DBK¼ desbenzylketo; GC-FID ¼ gas chromatography coupled to flame ionization detector; RT ¼ retention time.
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Table 2, indicating the linearity of the calibration curve.
3.2.2. Precision
The mean content (±standard deviation) of lumefantrine in
the intraday precision analysis (n ¼ 6) was 96.1% lc ± 0.9%
(RSD ¼ 0.9%), while that of the interday precision analysis
(n ¼ 18) was 96.3% lc ± 0.8% (RSD ¼ 0.9%). The intra- and
interday precision %RSD values were lower than 2.0%,
demonstrating appropriate precision of the method [29].
3.2.3. Accuracy (recovery test)
The recovery test was performed by analyzing a spiked pla-
cebo. Lumefantrine mean recovery was 99.5% (RSD ¼ 1.0%),
indicating the accuracy of the method.
3.2.4. Specificity
The chromatogram obtained for the mixture of lumefantrine
API and its related impurities (Fig. 2) showed no relatedTable 2 e Calibration curve for lumefantrine.
Regression parameters Lumefantrine
Regression coefficient, R2 0.9986
Slope ± standard error 13,085.77 ± 279.09
Intercept ± standard error 735,783.40 ± 140,932.86
Relative standard error (%) 2.13
Concentration range (mg/mL) 400e600
F value 2198.44
Number of points 5impurity peak interference with the main peak, proving that
themethod can be used for the quantification of lumefantrine
in the presence of its related impurities, including its possible
degradation products. Moreover, in the analyzed placebo
samples, we did not observe any interfering peak from the
excipients with the main peak.
3.2.5. Robustness of derivatization procedure
The optimum derivatization conditions were set up to BSTFA
solution in airtight glass vials at 70C for 30 minutes in an
oven. A composite face-centered design was applied to opti-
mize the sample derivatization process.
Two factors, incubation time (from 20 minutes to 40 mi-
nutes) and incubation temperature (from 60C to 80C), that
affect the yield of derivatization were considered. The factor
levels are indicated in the supplementary information. Maxi-
mization of peak area of the derivatized analyte was the target
of the optimization process. The coefficient plot for peak area
(presented in the supplementary information) displays the
regression coefficients with the 95% confidence interval (CI)
for the linear and quadratic effects of incubation time (Time)
and incubation temperature (Temp), and the product of the
time and temperature. None of the regression coefficients
differed significantly from zero. Therefore, the effect of both
variables and their product on peak area is considered not
significant at 95% CI. Optimal and most robust conditions
were assigned to the midpoints (0 level), i.e., incubation tem-
perature of 70C and incubation time of 30 minutes.
Moreover, no other peak was observed above the reporting
threshold of 0.1%, indicating that the derivatization mixture
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gion, defined as 70 ± 10C and 30 ± 10 minutes.
3.2.6. Robustness of chromatography
The PlacketteBurman design, a two-level fractional factorial
design, was used to test the robustness of the chromato-
graphic part of the method. This design is selected for
robustness evaluation since it combines less experimentation
with maximal information acquisition in the most efficient
way.Fig. 3 e Contour plots of the different chromatographic factors
lumefantrine.Four factors, with deliberate small deviations from the
method settings, were considered: injection temperature
(from290C to 310C), final column temperature (from320C to
330C), temperature gradient (from 8C/min to 12C/min), and
pressure (from 102 kPa to 112 kPa). The results of this design
are given in the supplementary information.
The contour plots of these chromatographic factors for
lumefantrine peak resolution (Rs) from N-oxide lumefantrine
are presented in Fig. 3AeF, while Rs from lumefantrine-related
compound A is presented in the supplementary information
(Fig. S3AeF). All Rs results from both N-oxide lumefantrine andfor lumefantrine peak resolution (Rs) from N-oxide
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small deviations introduced in the fourmethod parameters did
not have a significant effect on theminimal Rs specification set
in European Pharmacopoeia (Ph. Eur.)., which was defined as a
critical method attribute [30,31]. The RT for DBK was 20.54 mi-
nutes,while that of lumefantrinemainpeakwas 26.04minutes,
indicating a clear and noncritical separation of these twopeaks.
The injection temperature, final column temperature, and
pressure did not have a statistically significant effect on the RT
of lumefantrine at 95% CI, although the RT was increasing
from 24.6 minutes to 27.0 minutes with the decrease in the
final column temperature from the (þ) level (330C) to the ()
level (320C), and the same was true for pressure. An increase
in temperature gradient from 8C/min to 12C/min led to the
decrease in RT from 31.3 minutes to 22.6 minutes.
The effect of the deviations of the four chromatographic
parameters from the method setting on peak area, peak
asymmetry (As), and LoD was also evaluated (see
supplementary information), and the effect of these four pa-
rameters was not significant at 95% CI. Moreover, all the re-
sults of the peak asymmetry As comply with the set
specification in Ph. Eur. [30].
Therefore, the deviations from the target method setting
for the four parameters, injection temperature, final column
temperature, temperature gradient, and pressure, did not
affect the chromatographic parameter specifications,
revealing the robustness of the developed GC method.
3.2.7. LoD and LoQ
LoD and LoQ of lumefantrine were estimated based on the
signal-to-noise ratio. According to the determined signal-to-
noise ratio, the LoD and LoQ for lumefantrine were calcu-
lated to be 0.01 mg/mL and 0.04 mg/mL, respectively, indicating
the sensitivity of the method.
Moreover, the newGC-FIDmethod for the determination of
lumefantrine in FDC products has more sensitivity (lower LoD
and LoQ values) than the RP-C18 HPLC (LoD: 0.02 mg/mL and
LoQ: 0.05 mg/mL) and the fused-core HPLC (LoD: 0.10 mg/mL
and LoQ: 0.40 mg/mL) methods described in the literature
[12,16].3.3. Analysis of marketed FDC products
Table 3 gives the assay results of marketed samples obtained
in Ethiopia. The lumefantrine content varied from 96.2% to
98.3% lc, within the 90e110% lc specifications [23]. The resultsTable 3e Contents of lumefantrine in FDC products (n¼ 6
for each).
FDC samples Batch/
lot no.
Lumefantrine mean
content ±SD
Artemine tablets 7711 96.5 ± 0.4
7976 96.6 ± 1.0
Coartem tablets F2010 96.2 ± 0.6
F2006 96.4 ± 0.9
Co-Artesiane powder for
oral suspension
20460 98.3 ± 0.7
FDC ¼ fixed-dose combination; SD ¼ standard deviation.were found to be comparable to the assay results obtained on
the same samples using fused-core HPLC method,
97.9e101.5% lc [16].4. Conclusion
A GC-FID method for lumefantrine assay in pharmaceutical
preparations was developed and validated within an analyt-
ical quality-by-design approach. Themethod is linear, precise,
and sensitive. It makes use of simple sample preparation
procedures and is not solvent consuming. The RT of lume-
fantrinewas 26.0minutes, and therewas no interference from
its related synthesis and degradation impurities and excipi-
ents. The developed method was successfully applied to
analyze lumefantrine content in different marketed antima-
larial FPPs and can thus be applied to routine quality control of
lumefantrine in pharmaceutical preparations.Conflicts of interest
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